Drugs / 89Zr˗DFO˗REGN3504
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03746704 | Sep 2019 → Jul 2021 | cancer | Regeneron Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr˗DFO˗REGN3504 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03746704 ↗ |
| Modality | Diagnostic / imaging agent | “an Anti-PD-L1 Tracer for Positron Emission Tomography” NCT03746704 ↗ |